fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Clindamycin phosphate & adapalene & benzoyl peroxide

All products: Limited Use (codes 724)

Cabtreo · DIN 02550423 · 1.2% w/w & 0.15% w/w & 3.1% w/w · Top Gel Pump

Limited Use, Reason for Use code 724 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 724 required
Write on scriptReason for Use code 724 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 724
Reason for Use code 724 For the treatment of acne vulgaris in patients 12 years of age and older. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Cabtreo · DIN 02550423 Manufacturer: Bausch Health Canada Inc.; listing date 2025-06-30 Health Canada: Marketed since 2024-10-07 · brand CABTREO · ATC D10AF51 CLINDAMYCIN, COMBINATIONS · form Gel · route Topical · ingredients ADAPALENE 0.15 %/W/W, BENZOYL PEROXIDE 3.1 %/W/W, CLINDAMYCIN PHOSPHATE 1.2 %/W/W · company Bausch health, canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Cabtreo: Formulary list price $3.01 per unit (the source does not state the unit; exact figure $3.0074). What the ministry pays, not the patient.

Ministry pays: $3.0074 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02550423)

Source record
DIN 02550423: Cabtreo Raw flags: sec12=Y, sec3=Y Item: 840404031; group id 810; item number 1988; lccId 00411; manufacturer id BHC Source form: Top Gel Pump; strength: 1.2% w/w & 0.15% w/w & 3.1% w/w Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.0074; ministry $3.0074 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02550423 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103924
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02550423
Shortage record checked October 6, 2026

Other products in the same Health Canada class (D10AF): coverage varies; not interchangeable

  • Benzoyl peroxide + clindamycin (Clindoxyl): general benefit
  • Clindamycin (Dalacin T 1%): not a benefit
Other drugs in the same formulary class (84:04:04 Antibiotics) and how they are covered

Matched class: 84:04:04 Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE, FUSIDIC ACID, MUPIROCIN CALCIUM, SODIUM FUSIDATE Some products covered without a code (check the product listing): MUPIROCIN 84:04:04 Antibiotics

CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE

· 4 products · General benefit · strengths: 1% & 5% · Gel, Top Gel

CLINDAMYCIN

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% · Top Sol

FUSIDIC ACID

· 2 products · General benefit · strengths: 2% · Cr

MUPIROCIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Oint

MUPIROCIN CALCIUM

· 1 products · General benefit · strengths: 2% w/w · Cr

SODIUM FUSIDATE

· 2 products · General benefit · strengths: 2% · Oint Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:04:04
Full class listing Related classes: 84:04:08 Fungicides, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: acne
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CLINDAMYCIN · Off-Formulary Interchangeable, not an ODB benefit INDICATIONS AND CLINICAL USE Taro-Clindamycin 1% (clindamycin phosphate) is indicated for the treatment of acne vulgaris. PM: https://pdf.hres.ca/dpd_pm/00058691.PDF; date not captured; DIN 02266938; fetched 2026-09-10 Product monograph TAZAROTENE · Limited Use, codes 636 1 INDICATIONS ARAZLO™ (tazarotene lotion), is indicated for: • For the topical treatment of acne vulgaris in patients 10 years of age and older. 1.1 Pediatrics Pediatrics (≥ 10 years of age) The safety and efficacy of ARAZLO in pediatric patients (10 years of age and older) has been established. PM: https://pdf.hres.ca/dpd_pm/00082613.PDF; date NOV 28, 2025; DIN 02517868; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. CABTREO contains an antibacterial ingredient, clindamycin. To reduce the risk of development of drug-resistant bacteria and maintain the effectiveness of clindamycin, CABTREO should only be used for the authorized indication and clinical use. 1.1 Pediatrics Pediatrics (< 12 years of age): The safety and efficacy of CABTREO in pediatric patients (12 years of age and older) have been established; therefore, Health Canada has authorized an indication for pediatric patients (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics (> 65 years of age): A limited number of subjects aged ≥ 65 years have been treated with CABTREO in clinical trials; therefore, the safety and efficacy of CABTREO have not been established in this patient population (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00076715.PDF PM date: AUG 14, 2024 Source product: CABTREO; DIN 02550423; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.